| Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam C De la Calle, O Rodríguez, L Morata, F Marco, C Cardozo, ... International journal of antimicrobial agents 53 (4), 520-524, 2019 | 82 | 2019 |
| Current time-to-positivity of blood cultures in febrile neutropenia: a tool to be used in stewardship de-escalation strategies P Puerta-Alcalde, C Cardozo, M Suárez-Lledó, O Rodríguez-Núñez, ... Clinical Microbiology and Infection 25 (4), 447-453, 2019 | 65 | 2019 |
| Clinical characteristics and outcome of elderly patients with community-onset bacteremia C Hernández, C Fehér, A Soriano, F Marco, M Almela, N Cobos-Trigueros, ... Journal of Infection 70 (2), 135-143, 2015 | 59 | 2015 |
| Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study C Fehér, M Rovira, A Soriano, J Esteve, JA Martínez, F Marco, E Carreras, ... Journal of Antimicrobial Chemotherapy 69 (9), 2556-2562, 2014 | 58 | 2014 |
| A Comparison of Current Guidelines of Five International Societies on Clostridium difficile Infection Management C Fehér, J Mensa Infectious Diseases and Therapy 5 (3), 207-230, 2016 | 56 | 2016 |
| Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa O Rodríguez-Núñez, M Ripa, L Morata, C de la Calle, C Cardozo, C Fehér, ... Journal of global antimicrobial resistance 15, 136-139, 2018 | 48 | 2018 |
| Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection D Viasus, P Puerta-Alcalde, C Cardozo, M Suárez-Lledó, ... Clinical Microbiology and Infection 26 (3), 345-350, 2020 | 38 | 2020 |
| How Hyperprolactinemia Affects Sexual Function in Patients Under Antipsychotic Treatment E Rubio-Abadal, N Del Cacho, G Saenz-Navarrete, B Arranz, RM Cambra, ... Journal of Clinical Psychopharmacology 36 (5), 422-428, 2016 | 34 | 2016 |
| The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort C Fehér, EM Rubio, PM Amador, ADI Garcia-Campero, M Salavert, ... European Journal of Clinical Microbiology & Infectious Diseases 36 (2), 295-303, 2017 | 30 | 2017 |
| The intestinal microbiota as a reservoir and a therapeutic target to fight multi-drug-resistant bacteria: a narrative review of the literature A Aira, C Fehér, E Rubio, A Soriano Infectious diseases and therapy 8 (4), 469-482, 2019 | 29 | 2019 |
| Community-onset bacteraemia of unknown origin: clinical characteristics, epidemiology and outcome C Hernandez, N Cobos-Trigueros, C Feher, L Morata, C De La Calle, ... European Journal of Clinical Microbiology and Infectious Diseases 33 (11), 1973, 2014 | 28 | 2014 |
| Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted … M Ripa, O Rodríguez-Núñez, C Cardozo, A Naharro-Abellán, M Almela, ... Journal of Antimicrobial Chemotherapy 72 (12), 3443-3452, 2017 | 27 | 2017 |
| A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection C Fehér, A Soriano, J Mensa Infectious diseases and therapy 6 (1), 1, 2017 | 25 | 2017 |
| rUTI resolution after FMT for clostridioides difficile infection: a case report A Aira, E Rubio, A Vergara Gómez, C Fehér, C Casals-Pascual, ... Infectious Diseases and Therapy 10 (2), 1065-1071, 2021 | 22 | 2021 |
| Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response L Leal, C Fehér, V Richart, B Torres, F García Vaccines 8 (3), 442, 2020 | 14 | 2020 |
| High rate of long-term clinical events after antiretroviral therapy resumption in HIV-positive patients exposed to antiretroviral therapy interruption V Richart, I Fernández, E de Lazzari, L Berrocal, C Fehér, M Plana, L Leal, ... AIDS 35 (15), 2463-2468, 2021 | 7 | 2021 |
| Virological Outcome Measures During Analytical Treatment Interruptions in Chronic HIV-1-Infected Patients C Fehér, L Leal, M Plana, N Climent, A Crespo Guardo, E Martínez, ... Open Forum Infectious Diseases 6 (12), ofz485, 2019 | 7 | 2019 |
| Multiple imputation approach for interval‐censored time to HIV RNA viral rebound within a mixed effects Cox model Y Alarcón‐Soto, K Langohr, C Fehér, F García, G Gómez Biometrical Journal 61 (2), 299-318, 2019 | 7 | 2019 |
| Association of Transcriptomic Signatures of Inflammatory Response with Viral Control after Dendritic Cell-Based Therapeutic Vaccination in HIV-1 Infected Individuals C Fehér, R Pastor-lbáñez, L Leal, M Plana, M Arnedo, HJ van den Ham, ... Vaccines 9 (7), 799, 2021 | 4 | 2021 |
| A Classifier to Predict Viral Control After Antiretroviral Treatment Interruption in Chronic HIV-1–Infected Patients C Fehér, M Plana, AC Guardo, N Climent, L Leal, A Ugarte, I Fernández, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 83 (5), 479-485, 2020 | 3 | 2020 |
